Anatomical Therapeutic Chemical • L04AG • Monoclonal antibodies

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AF Janus-associated kinase (JAK) inhibitors

L04AG Monoclonal antibodies

L04AG05 vedolizumab Indicated for: inflammatory bowel disease

L04AG08 ocrelizumab Indicated for: multiple sclerosis

L04AG11 anifrolumab Indicated for: systemic lupus erythematosus

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AL Neonatal fragment crystallizable receptor (fcrn) inhibitors

L04AX Other immunosuppressants